Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-Current Assets (2016 - 2025)

Traws Pharma's Non-Current Assets history spans 14 years, with the latest figure at $2.6 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $2.6 million for Q4 2025, up 23881.82% from a year ago — trailing twelve months through Dec 2025 was $5.9 million (up 10098.28% YoY), and the annual figure for FY2025 was $2.6 million, up 23881.82%.
  • Non-Current Assets for Q4 2025 was $2.6 million at Traws Pharma, down from $2.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.8 million in Q3 2025 to a low of $11000.0 in Q4 2024.
  • The 5-year median for Non-Current Assets is $35000.0 (2022), against an average of $334450.0.
  • The sharpest move saw Non-Current Assets plummeted 77.84% in 2022, then skyrocketed 23881.82% in 2025.
  • Year by year, Non-Current Assets stood at $48000.0 in 2021, then crashed by 47.92% to $25000.0 in 2022, then dropped by 8.0% to $23000.0 in 2023, then crashed by 52.17% to $11000.0 in 2024, then skyrocketed by 23881.82% to $2.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $2.6 million, $2.8 million, and $252000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.